TW202233666A - 減少人類對象中之tau的方法 - Google Patents
減少人類對象中之tau的方法 Download PDFInfo
- Publication number
- TW202233666A TW202233666A TW110139444A TW110139444A TW202233666A TW 202233666 A TW202233666 A TW 202233666A TW 110139444 A TW110139444 A TW 110139444A TW 110139444 A TW110139444 A TW 110139444A TW 202233666 A TW202233666 A TW 202233666A
- Authority
- TW
- Taiwan
- Prior art keywords
- amino acid
- seq
- acid sequence
- chain variable
- days
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105804P | 2020-10-26 | 2020-10-26 | |
| US63/105,804 | 2020-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202233666A true TW202233666A (zh) | 2022-09-01 |
Family
ID=78402146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110139444A TW202233666A (zh) | 2020-10-26 | 2021-10-25 | 減少人類對象中之tau的方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220127345A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4232155A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023546504A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230093499A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116916955A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021367878A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3199806A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302386A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004831A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202233666A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022090158A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201946654A (zh) | 2018-03-05 | 2019-12-16 | 比利時商健生藥品公司 | 抗PHF-Tau抗體及其用途 |
| JP7379764B1 (ja) | 2022-08-09 | 2023-11-15 | レール・リキード-ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード | 空気分離装置および空気分離方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| CN107095846A (zh) * | 2009-12-21 | 2017-08-29 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| ITMI20120814A1 (it) * | 2012-05-11 | 2013-11-12 | Diego Dolcetta | Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche |
| US8980270B2 (en) * | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| EP3551655A2 (en) * | 2016-12-07 | 2019-10-16 | Genentech, Inc. | Anti-tau antibodies and methods of their use |
| TWI771389B (zh) * | 2017-03-16 | 2022-07-21 | 美商健生生物科技公司 | 抗phf-tau抗體及其用途 |
| CN117205311A (zh) * | 2017-03-28 | 2023-12-12 | 基因泰克公司 | 治疗神经退行性疾病的方法 |
| WO2019171258A1 (en) * | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
| US20230075314A1 (en) * | 2019-04-29 | 2023-03-09 | Voyager Therapeutics, Inc. | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF |
| JP2023546503A (ja) * | 2020-10-26 | 2023-11-02 | ヤンセン ファーマシューティカ エヌ.ベー. | 抗タウ抗体の安全な投与方法 |
-
2021
- 2021-10-25 AU AU2021367878A patent/AU2021367878A1/en active Pending
- 2021-10-25 WO PCT/EP2021/079543 patent/WO2022090158A1/en not_active Ceased
- 2021-10-25 KR KR1020237017869A patent/KR20230093499A/ko active Pending
- 2021-10-25 JP JP2023525044A patent/JP2023546504A/ja active Pending
- 2021-10-25 TW TW110139444A patent/TW202233666A/zh unknown
- 2021-10-25 CA CA3199806A patent/CA3199806A1/en active Pending
- 2021-10-25 IL IL302386A patent/IL302386A/en unknown
- 2021-10-25 EP EP21798703.1A patent/EP4232155A1/en active Pending
- 2021-10-25 MX MX2023004831A patent/MX2023004831A/es unknown
- 2021-10-25 US US17/509,889 patent/US20220127345A1/en not_active Abandoned
- 2021-10-25 CN CN202180087530.2A patent/CN116916955A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4232155A1 (en) | 2023-08-30 |
| AU2021367878A1 (en) | 2023-06-22 |
| US20220127345A1 (en) | 2022-04-28 |
| WO2022090158A1 (en) | 2022-05-05 |
| JP2023546504A (ja) | 2023-11-02 |
| KR20230093499A (ko) | 2023-06-27 |
| CA3199806A1 (en) | 2022-05-05 |
| MX2023004831A (es) | 2023-07-12 |
| CN116916955A (zh) | 2023-10-20 |
| IL302386A (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7241058B2 (ja) | 抗N3pGluアミロイドベータペプチド抗体およびその使用 | |
| RU2518351C2 (ru) | Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения | |
| CN106390107B (zh) | 病理tau蛋白的免疫靶向 | |
| TWI705824B (zh) | 治療阿茲海默症之方法 | |
| US20230123110A1 (en) | High dose treatments for alzheimer's disease | |
| TW201900682A (zh) | 抗phf-tau抗體及其用途 | |
| US20220127346A1 (en) | Methods of Safe Administration of Anti-Tau Antibody | |
| US20220127345A1 (en) | Methods of Reducing Tau in Human Subjects | |
| TW202543674A (zh) | 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途 | |
| JP2024547001A (ja) | 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法 | |
| Class et al. | Patent application title: Methods of Reducing Tau in Human Subjects | |
| EA052839B1 (ru) | Способы снижения уровня тау-белка у человеческих индивидов | |
| EA050381B1 (ru) | Способы снижения уровня тау-белка у человеческих индивидов | |
| HK40100364A (en) | Methods of reducing tau in human subjects | |
| JP2024509956A (ja) | 抗N3pGluアミロイドベータ抗体及びその使用 | |
| EA051320B1 (ru) | Способ безопасного введения антитела к тау-белку | |
| CN116829582A (zh) | 安全施用抗Tau抗体的方法 | |
| CN118450905A (zh) | 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法 | |
| HK40100358A (en) | Method of safe administration of anti-tau antibody | |
| HK1261507A1 (en) | High dose treatments for alzheimer's disease |